Synchronization of anti-tachycardia pacing in an extra-cardiovascular implantable system

Patent metadata

Field	Value
Publication number	US-11752344-B2
Application number	US-202117323008-A
Country	US
Kind code	B2
Filing date	May 18, 2021
Priority date	Mar 16, 2016
Publication date	Sep 12, 2023
Grant date	Sep 12, 2023

Abstract

An extra-cardiovascular implantable cardioverter defibrillator (ICD) system receives a cardiac electrical signal by an electrical sensing circuit via an extra-cardiovascular sensing electrode vector and senses cardiac events from the cardiac electrical signal. The ICD system detects tachycardia from the cardiac electrical signal and determines a tachycardia cycle length from the cardiac electrical signal. The ICD system determines an ATP interval based on the tachycardia cycle length and sets an extended ATP interval that is longer than the ATP interval. The ICD delivers ATP pulses to a patient's heart via an extra-cardiovascular pacing electrode vector different than the sensing electrode vector. The ATP pulses include a leading ATP pulse delivered at the extended ATP interval after a cardiac event is sensed from the cardiac electrical signal and a second ATP pulse delivered at the ATP interval following the leading ATP pulse.

First claim

The invention claimed is:

1. A medical device, comprising:
a sensing circuit configured to:
receive a first cardiac electrical signal; and
sense first cardiac events each associated with a myocardial depolarization from the first cardiac electrical signal;

a control circuit coupled to the sensing circuit and configured to:
detect tachycardia from the first cardiac electrical signal;
set an ATP interval; and
set a first extended ATP interval that is longer than the ATP interval; and

a therapy delivery circuit coupled to the control circuit and configured to deliver a first therapy following the detection of the tachycardia by the control circuit by:
delivering a first leading ATP pulse at the first extended ATP interval from a first one of the first cardiac events sensed by the sensing circuit from the first cardiac electrical signal; and
delivering a second ATP pulse at the ATP interval from the first leading ATP pulse.

2. The medical device of claim 1 , wherein the control circuit is further configured to set the ATP interval by:
determining a tachycardia cycle length from the first cardiac electrical signal; and
setting the ATP interval to be less than the tachycardia cycle length.

3. The medical device of claim 2 , wherein the control circuit is further configured to set the first extended ATP interval to the determined tachycardia cycle length.

4. The medical device of claim 1 , wherein:
the control circuit is further configured to:
re-detect the tachycardia from the first cardiac electrical signal after the first therapy is delivered by the therapy delivery circuit; and
in response to re-detecting the tachycardia, set a second extended ATP interval different than the first extended ATP interval; and

the therapy delivery circuit is further configured to deliver a second therapy following the re-detection of the tachycardia by the control circuit by:
delivering a second leading ATP pulse delivered at the second extended ATP interval from a second one of the first cardiac events sensed by the sensing circuit from the first cardiac electrical signal; and
delivering a third ATP pulse at the ATP interval from the second leading ATP pulse.

5. The medical device of claim 4 , wherein the control circuit is further configured to set the second extended ATP interval based on at least the first extended ATP interval.

6. The medical device of claim 5 , wherein the control circuit is further configured to set the second extended ATP interval based on at least the first extended ATP interval by:
determining a tachycardia cycle length from the first cardiac electrical signal; and
setting the second extended ATP interval based on the determined tachycardia cycle length and the first extended ATP interval.

7. The medical device of claim 5 , wherein:
the sensing circuit is further configured to:
receive a second cardiac electrical signal different than the first cardiac electrical signal; and
sense second cardiac events each associated with a myocardial depolarization from the second cardiac electrical signal;

the control circuit is further configured to:
determine a time difference from a first cardiac event sensed by the sensing circuit from the first cardiac electrical signal to a second cardiac event sensed by the sensing circuit from the second cardiac electrical signal; and
set the second extended ATP interval based on the first extended ATP interval and the time difference.

8. The medical device of claim 1 , wherein:
the control circuit is further configured to:
determine a tachycardia cycle length from the first cardiac electrical signal;
determine an actual prematurity of the first leading pulse as the tachycardia cycle length minus the first extended ATP interval plus the time difference; and
determine a total prematurity of the first therapy including the actual prematurity of the first leading pulse; and

the therapy delivery circuit is further configured to deliver the second therapy having a total prematurity that is greater than the total prematurity of the first therapy.

9. The medical device of claim 8 , wherein the therapy delivery circuit is further configured to:
deliver the first therapy by delivering a first number of ATP pulses after the second ATP pulse; and
deliver the second therapy having the total prematurity that is greater than the total prematurity of the first therapy by at least one of:
delivering a second number of ATP pulses after the third ATP pulse, the second number of ATP pulses being greater than the first number of ATP pulses; and
decreasing the ATP interval.

10. The medical device of claim 1 , further comprising a housing configured to receive an extra-cardiovascular lead.

11. A method, comprising:
receiving a first cardiac electrical signal;
sensing first cardiac events that are each associated with a myocardial depolarization from the first cardiac electrical signal;
detecting tachycardia from the first cardiac electrical signal;
setting an ATP interval;
setting a first extended ATP interval that is longer than the ATP interval; and
delivering a first therapy following the detection of the tachycardia by:
delivering a first leading ATP pulse at the first extended ATP interval from a first one of the first cardiac events sensed from the first cardiac electrical signal; and
delivering a second ATP pulse at the ATP interval from the first leading ATP pulse.

12. The method of claim 11 , wherein setting the ATP interval comprises:
determining a tachycardia cycle length from the first cardiac electrical signal; and
setting the ATP interval to be less than the tachycardia cycle length.

13. The method of claim 12 , wherein setting the first extended ATP interval comprises setting the first extended ATP interval to the determined tachycardia cycle length.

14. The method of claim 11 , further comprising:
re-detecting the tachycardia from the first cardiac electrical signal after delivering the first therapy;
in response to re-detecting the tachycardia, setting a second extended ATP interval different than the first extended ATP interval; and
delivering a second therapy after redetecting the tachycardia by:
delivering a second leading ATP pulse delivered at the second extended ATP interval from a second one of the first cardiac events sensed from the first cardiac electrical signal; and
delivering a third ATP pulse at the ATP interval from the second leading ATP pulse.

15. The method of claim 14 , further comprising setting the second extended ATP interval based on at least the first extended ATP interval.

16. The method of claim 15 , wherein setting the second extended ATP interval based on at least the first extended ATP interval comprises:
determining a tachycardia cycle length from the first cardiac electrical signal; and
setting the second extended ATP interval based on the determined tachycardia cycle length and the first extended ATP interval.

17. The method of claim 15 , further comprising:
receiving a second cardiac electrical signal different than the first cardiac electrical signal;
sensing second cardiac events each associated with a myocardial depolarization from the second cardiac electrical signal;
determining a time difference from a first cardiac event sensed from the first cardiac electrical signal to a second cardiac event sensed from the second cardiac electrical signal; and
setting the second extended ATP interval based on the first extended ATP interval and the time difference.

18. The method of claim 17 , further

Assignees

• Medtronic Inc

Inventors

• Jackson Troy E

Classifications

• A61N1/0504 Primary

  Subcutaneous electrodes · CPC title

• A61N1/3621 Primary

  for treating or preventing abnormally high heart rate · CPC title

• A61N1/0563

  specially adapted for defibrillation or cardioversion · CPC title

• A61N1/36514

  controlled by a physiological quantity other than heart potential, e.g. blood pressure (controlled by two or more physical parameters A61N1/36585) · CPC title

• A61N1/3962

  in combination with another heart therapy · CPC title